Cite

Abstract P6-15-09: Final results of weekly (w) neoadjuvant carboplatin (Cp) added to paclitaxel (P) followed by epirubicin (E) and cyclophosphamide (C) in triple negative breast cancer (TNBC) patients (pts): A BSMO breast cancer task force phase II study

MLA

Heidi Van den Bulck, et al. “Abstract P6-15-09: Final Results of Weekly (w) Neoadjuvant Carboplatin (Cp) Added to Paclitaxel (P) Followed by Epirubicin (E) and Cyclophosphamide (C) in Triple Negative Breast Cancer (TNBC) Patients (Pts): A BSMO Breast Cancer Task Force Phase II Study.” Cancer Research, vol. 78, Feb. 2018, pp. P6-15. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi...........d47c6ae1b80ef3b0a11ae6719962f7d0&authtype=sso&custid=ns315887.



APA

Heidi Van den Bulck, Hans Wildiers, Lore Decoster, Christel Fontaine, Jacques De Greve, Ahmed Awada, Peter Vuylsteke, Catherine Dopchie, Nadia Cappoen, V. Renard, & P Glorieux. (2018). Abstract P6-15-09: Final results of weekly (w) neoadjuvant carboplatin (Cp) added to paclitaxel (P) followed by epirubicin (E) and cyclophosphamide (C) in triple negative breast cancer (TNBC) patients (pts): A BSMO breast cancer task force phase II study. Cancer Research, 78, P6-15.



Chicago

Heidi Van den Bulck, Hans Wildiers, Lore Decoster, Christel Fontaine, Jacques De Greve, Ahmed Awada, Peter Vuylsteke, et al. 2018. “Abstract P6-15-09: Final Results of Weekly (w) Neoadjuvant Carboplatin (Cp) Added to Paclitaxel (P) Followed by Epirubicin (E) and Cyclophosphamide (C) in Triple Negative Breast Cancer (TNBC) Patients (Pts): A BSMO Breast Cancer Task Force Phase II Study.” Cancer Research 78 (February): P6-15. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi...........d47c6ae1b80ef3b0a11ae6719962f7d0&authtype=sso&custid=ns315887.